Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 3
1963 3
1964 3
1965 3
1966 1
1967 1
1968 4
1970 4
1977 1
1978 1
1979 1
1981 1
1983 4
1984 5
1985 5
1986 7
1987 10
1988 12
1989 12
1990 6
1991 8
1992 12
1993 9
1994 5
1995 11
1996 8
1997 9
1998 20
1999 19
2000 16
2001 26
2002 14
2003 16
2004 20
2005 21
2006 21
2007 24
2008 24
2009 26
2010 35
2011 33
2012 37
2013 54
2014 48
2015 57
2016 73
2017 80
2018 65
2019 66
2020 70
2021 57
2022 56
Text availability
Article attribute
Article type
Publication date

Search Results

1,023 results
Results by year
Filters applied: . Clear all
Page 1
Home exercise therapy to improve muscle strength and joint flexibility effectively treats pre-radiographic knee OA in community-dwelling elderly: a randomized controlled trial.
Suzuki Y, Iijima H, Tashiro Y, Kajiwara Y, Zeidan H, Shimoura K, Nishida Y, Bito T, Nakai K, Tatsumi M, Yoshimi S, Tsuboyama T, Aoyama T. Suzuki Y, et al. Among authors: iijima h. Clin Rheumatol. 2019 Jan;38(1):133-141. doi: 10.1007/s10067-018-4263-3. Epub 2018 Aug 30. Clin Rheumatol. 2019. PMID: 30167975 Free PMC article. Clinical Trial.
Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Nishikawa H, et al. Among authors: iijima h. Int J Mol Sci. 2020 Jul 24;21(15):5254. doi: 10.3390/ijms21155254. Int J Mol Sci. 2020. PMID: 32722100 Free PMC article. Review.
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan). Hiraoka A, et al. Among authors: iijima h. Cancer Rep (Hoboken). 2022 Feb;5(2):e1464. doi: 10.1002/cnr2.1464. Epub 2021 Jun 11. Cancer Rep (Hoboken). 2022. PMID: 34114752 Free PMC article.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Hiraoka A, et al. Among authors: iijima h. Hepatol Res. 2022 Mar;52(3):308-316. doi: 10.1111/hepr.13734. Epub 2021 Dec 2. Hepatol Res. 2022. PMID: 34799975
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: iijima h. Cancer Med. 2022 Jun 3. doi: 10.1002/cam4.4854. Online ahead of print. Cancer Med. 2022. PMID: 35666040 Free article.
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: iijima h. Cancer Med. 2022 Oct;11(20):3796-3808. doi: 10.1002/cam4.4763. Epub 2022 Apr 19. Cancer Med. 2022. PMID: 35441477 Free PMC article.
1,023 results